2nd Annual Advances in Immuno-Oncology Congress 2017

Over 150 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.

More than 30 presentations, case studies and panel discussions focused on the key issues in immuno-oncology, from across two interactive streams:

• Designing Immuno-oncology Therapies
• Immuno-Oncology: Therapeutic Approaches & Clinical Trials

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Oxford Global Conferences are proud to present our 2nd Annual Advances in Immuno-Oncology Congress, taking place on the 15-16 May 2017 in London.

Discovering new ways to effectively target and treat cancer is one of the most pressing challenges for the pharmaceutical industry today. The field of immuno-oncology is currently predicted to reach a value totalling $25 billion annually by 2020. At this crucial time of growth and advancement, this congress offers invaluable insights into key technological and scientific innovations. Addressing the main challenges and opportunities in the industry, delegates will learn more about hot areas including the discovery of novel viral, antibody and cell-based therapies, clinical partnerships and approaches to combination therapies.

Our first day will feature two streams. Stream one will focus on discovery and early development issues for cancer immunotherapies, with presentations providing a comprehensive look at therapeutic strategies. Our expert panel of speakers will discuss the latest advances in the areas of checkpoint inhibitors, agonist antibodies and viral therapy development. Attendees will have the opportunity to hear the latest on the engineering of T-cells, studies in B cell biology, animal models and toxicity issues.

Our second stream on day one will cover clinical trials and later therapeutic approaches, including combination therapies and industry collaborations. Senior experts from innovative biotech organisations as well as large pharma will discuss their clinical data, address safety challenges in immuno-oncology development and partnership opportunities. Speakers will also present up-to-the-minute news on topics including clinical biomarker development.

Day two will focus on later preclinical development, with topics including preclinical biomarkers, trial design and case studies of immunotherapies currently in the late preclinical and early clinical stages. Speakers will also discuss modelling, with a focus on the use of humanised mouse models. Presentations also include a discussions on preclinical combinations and in vivo imaging to evaluate biodistribution.

This exciting new event will attract senior-level decision makers working at the forefront of the immuno-oncology industry from across Europe and the USA. The conference programme consists of world-class keynote addresses, industry and academic led presentations and panel debates, as well as ample networking opportunities, creating an interactive platform for high-level scientific and business discussion.

The Advances in Immuno-Oncology Congress is part of the highly successful Oxford Global Biologics Series. For more information on other events in the series, please see the details below:


Media Partners